Moderna begins COVID-19 vaccine trial in teenagers

Moderna Vaccine
Posted at 11:51 AM, Dec 10, 2020
and last updated 2020-12-10 11:52:59-05

Moderna announced Thursday they have started giving teenagers their COVID-19 vaccine as part of their study on how the vaccine works in those under 18.

Pfizer, the other vaccine maker with an emergency use request for their COVID-19 vaccine in adults before the FDA, started including teens in their trial in October.

In the Moderna’s press release, they say the Phase 2/3 study of the mRNA vaccine is now underway and is being conducted on children between the ages of 12 and 18.

“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy adolescents in the U.S. Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year,” said Stéphane Bancel, Chief Executive Officer of Moderna in a company statement. “We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting.”

The Phase 2/3 study from Moderna is being done to test the safety and immunogenicity of the two-dose vaccine they submitted to the FDA for emergency use approval last month.

They plan to enroll about 3,000 teenagers in the U.S. in the trial, with each receiving either a placebo or the vaccine in two doses, 28 days apart.

Download our streaming app on your favorite device.  Click here for more.

Download our streaming app on your favorite device. Click here for more.